Stock listing
LS Exchange:A3C7A5 MaaT Pharma Aktie
German listing (LS Exchange) of MaaT Pharma · home listing Euronext:MAAT
Follow MaaT Pharma into a list and get an email when it puts out news.
Home listing price · EURONEXT:MAAT
€0.78 EUR -0.12 (-13.3%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, EURONEXT:MAAT
- Day range
- €0.762 – €0.87 EURNov 20, 2026
- Volume
- 101,572 sharesNov 20, 2026
- Market cap
- €14.68M EURAt the close on Nov 20, 2026 · price × 18.82M shares outstanding
- 52-week range
- €0.762 – €8.62 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €146,383 EURMedian day 55,218 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:MAAT · Home | €0.78 EUR | -0.12 (-13.3%) | 101,572 | €0.87 | €0.87 | €0.762 | €0.90 | Close on Nov 20, 2026 |
| Frankfurt:4RD | €0.742 EUR | -0.098 (-11.7%) | — | €0.823 | €0.823 | €0.742 | €0.840 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · EURONEXT:MAAT · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.78 | -0.12 | -13.3% | €0.87 | €0.87 | €0.762 | 101,572 | |
| €0.90 | -0.102 | -10.2% | €1.00 | €1.00 | €0.90 | 178,357 | |
| €1.002 | -0.024 | -2.3% | €1.03 | €1.036 | €1.002 | 27,171 | |
| €1.026 | -0.002 | -0.2% | €1.03 | €1.056 | €1.026 | 47,611 | |
| €1.028 | -0.032 | -3.0% | €1.08 | €1.082 | €1.024 | 54,922 | |
| €1.06 | -0.01 | -0.9% | €1.10 | €1.10 | €1.052 | 58,651 | |
| €1.07 | -0.022 | -2.0% | €1.092 | €1.10 | €1.068 | 37,033 | |
| €1.092 | -0.002 | -0.2% | €1.148 | €1.148 | €1.092 | 46,093 | |
| €1.094 | +0.004 | +0.4% | €1.09 | €1.198 | €1.078 | 125,572 | |
| €1.09 | +0.09 | +9.0% | €1.064 | €1.27 | €1.02 | 340,355 | |
| €1.00 | -0.016 | -1.6% | €1.016 | €1.04 | €1.00 | 42,804 | |
| €1.016 | 0.00 | 0.0% | €1.016 | €1.038 | €1.014 | 24,874 | |
| €1.016 | -0.014 | -1.4% | €1.05 | €1.05 | €1.012 | 31,931 | |
| €1.03 | +0.012 | +1.2% | €1.02 | €1.04 | €1.01 | 24,531 | |
| €1.018 | -0.052 | -4.9% | €1.092 | €1.122 | €1.016 | 89,787 | |
| €1.07 | +0.028 | +2.7% | €1.042 | €1.09 | €1.03 | 71,712 | |
| €1.042 | -0.002 | -0.2% | €1.042 | €1.052 | €1.018 | 84,368 | |
| €1.044 | -0.018 | -1.7% | €1.07 | €1.07 | €1.038 | 42,221 | |
| €1.062 | -0.006 | -0.6% | €1.08 | €1.09 | €1.038 | 31,788 | |
| €1.068 | +0.006 | +0.6% | €1.12 | €1.12 | €1.058 | 37,054 | |
| €1.062 | -0.034 | -3.1% | €1.14 | €1.14 | €1.038 | 55,514 | |
| €1.096 | +0.076 | +7.5% | €1.05 | €1.19 | €1.014 | 198,814 | |
| €1.02 | +0.02 | +2.0% | €1.25 | €1.30 | €1.02 | 490,141 | |
| €1.00 | +0.01 | +1.0% | €0.99 | €1.026 | €0.982 | 57,407 | |
| €0.99 | +0.016 | +1.6% | €0.97 | €0.99 | €0.961 | 22,578 | |
| €0.974 | +0.033 | +3.5% | €0.951 | €0.974 | €0.93 | 23,905 | |
| €0.941 | +0.028 | +3.1% | €0.94 | €0.951 | €0.908 | 30,902 | |
| €0.913 | +0.005 | +0.6% | €0.93 | €0.93 | €0.912 | 11,589 | |
| €0.908 | -0.014 | -1.5% | €0.906 | €0.92 | €0.903 | 39,248 | |
| €0.922 | -0.008 | -0.9% | €0.95 | €0.95 | €0.904 | 22,293 | |
| €0.93 | -0.053 | -5.4% | €0.96 | €0.979 | €0.93 | 19,570 | |
| €0.983 | -0.007 | -0.7% | €0.99 | €0.991 | €0.95 | 61,084 | |
| €0.99 | +0.051 | +5.4% | €0.982 | €1.01 | €0.925 | 69,515 | |
| €0.939 | -0.071 | -7.0% | €1.01 | €1.014 | €0.916 | 195,649 | |
| €1.01 | -0.02 | -1.9% | €1.032 | €1.08 | €1.00 | 154,897 | |
| €1.03 | -0.054 | -5.0% | €1.09 | €1.186 | €1.01 | 112,846 | |
| €1.084 | -0.046 | -4.1% | €1.11 | €1.13 | €1.082 | 92,618 | |
| €1.13 | -0.01 | -0.9% | €1.25 | €1.25 | €1.13 | 73,643 | |
| €1.14 | +0.006 | +0.5% | €1.27 | €1.28 | €1.14 | 156,328 | |
| €1.134 | -0.128 | -10.1% | €1.296 | €1.296 | €1.134 | 137,369 | |
| €1.262 | -0.096 | -7.1% | €1.39 | €1.39 | €1.252 | 120,579 | |
| €1.358 | -0.072 | -5.0% | €1.388 | €1.418 | €1.312 | 130,781 | |
| €1.43 | +0.13 | +10.0% | €1.368 | €1.59 | €1.33 | 353,541 | |
| €1.30 | -0.33 | -20.2% | €1.63 | €1.66 | €1.30 | 315,707 | |
| €1.63 | -0.37 | -18.5% | €2.02 | €2.22 | €1.63 | 417,364 | |
| €2.00 | +0.56 | +38.9% | €1.44 | €2.00 | €1.44 | 422,021 | |
| €1.44 | +0.36 | +33.3% | €1.108 | €1.47 | €1.108 | 410,459 | |
| €1.08 | -1.435 | -57.1% | €1.06 | €1.16 | €1.00 | 444,282 | |
| €2.515 | -0.22 | -8.0% | €2.68 | €2.68 | €2.51 | 79,774 | |
| €2.735 | -0.055 | -2.0% | €2.78 | €2.88 | €2.70 | 33,087 | |
| €2.79 | +0.135 | +5.1% | €2.66 | €2.835 | €2.66 | 38,283 | |
| €2.655 | -0.145 | -5.2% | €2.75 | €2.785 | €2.65 | 34,428 | |
| €2.80 | -0.08 | -2.8% | €2.89 | €2.895 | €2.78 | 35,012 | |
| €2.88 | -0.06 | -2.0% | €2.96 | €2.96 | €2.80 | 28,531 | |
| €2.94 | +0.005 | +0.2% | €3.045 | €3.045 | €2.94 | 25,902 | |
| €2.935 | -0.025 | -0.8% | €2.96 | €2.965 | €2.92 | 13,621 | |
| €2.96 | -0.045 | -1.5% | €2.97 | €3.00 | €2.96 | 7,517 | |
| €3.005 | +0.045 | +1.5% | €3.00 | €3.075 | €2.965 | 27,930 | |
| €2.96 | -0.065 | -2.1% | €3.03 | €3.03 | €2.92 | 24,554 | |
| €3.025 | +0.005 | +0.2% | €3.03 | €3.075 | €2.96 | 28,125 | |
| €3.02 | +0.03 | +1.0% | €3.00 | €3.07 | €2.94 | 22,385 | |
| €2.99 | -0.05 | -1.6% | €3.05 | €3.06 | €2.98 | 23,536 | |
| €3.04 | -0.005 | -0.2% | €3.06 | €3.09 | €2.98 | 32,349 | |
| €3.045 | -0.145 | -4.5% | €3.28 | €3.28 | €2.955 | 80,235 | |
| €3.19 | +0.07 | +2.2% | €3.12 | €3.40 | €3.05 | 131,751 | |
| €3.12 | -0.03 | -1.0% | €3.26 | €3.38 | €3.065 | 77,249 |
- Ticker
- LS Exchange:A3C7A5
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LS Exchange
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
MaaT Pharma Reports Financial Results for the Third Quarter 2026
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 27 slides
Latest news
MaaT Pharma Reports Financial Results for the Third Quarter 2026
Nov 16, 2026
Closed €1.00 (-2.3%) on Nov 17, 2026
MaaT Pharma Provides an Update on Preliminary Findings from the Investigator-Sponsored Phase 2a PICASSO Trial in Metastatic Melanoma
Nov 6, 2026
Closed €1.09 (+9.0%) on Nov 6, 2026
MaaT Pharma Receives FDA Feedback Following Pre-IND Meeting Supporting Continued Development of MaaT034 in Solid Tumors
Oct 19, 2026
Closed €1.02 (+2.0%) on Oct 20, 2026
MaaT Pharma Publishes its Half-Year 2026 Results and Provides a Business Update
Sep 29, 2026
Closed €1.08 (-4.1%) on Sep 30, 2026
MaaT Pharma publie ses résultats semestriels 2026 et fait le point sur ses activités
Sep 29, 2026
Closed €1.13 (-0.9%) on Sep 29, 2026
MaaT Pharma Announces Upcoming Pre-IND Meeting with the FDA and Advances MaaT034 Toward Clinical Development in Solid Tumors
Sep 21, 2026
Closed €1.43 (+10.0%) on Sep 22, 2026
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination
Sep 18, 2026
Closed €1.63 (-18.5%) on Sep 18, 2026
MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 (Xervyteg®) Following Re-Examination for its Conditional Marketing Authorization Application in Europe
Sep 15, 2026
Closed €1.08 (-57.1%) on Sep 15, 2026
MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract
Jul 6, 2026
Closed €2.70 (-1.5%) on Jul 7, 2026
MaaT Pharma on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 23 in the last 12 months · 41 in all · newest Nov 16, 2026 · oldest 2025
- Decks
- 27 decks · latest October 2026
Where MaaT Pharma is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:MAAT · Home listing | Euronext | France | EUR |
| gettex:4RD | gettex | Germany | EUR |
| LS Exchange:A3C7A5 · This page | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3C7A5 | Lang & Schwarz | Germany | EUR |
| Frankfurt:4RD | Frankfurt | Germany | EUR |
| OTC:MATPF | OTC | United States | USD |
| Hamburg:4RD | Hamburg | Germany | EUR |
| Munich:4RD | Munich | Germany | EUR |
| Stuttgart:4RD | Stuttgart | Germany | EUR |
| Dusseldorf:4RD | Dusseldorf | Germany | EUR |
Valuation
EV/sales 4.7× against a median of 2.7×: 3rd lowest of 4 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €21.29M EUR
- P/E
- Loss
- EV/sales
- 4.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 30.7%
- Operating margin
- −754.9%
- Net margin
- −686.6%
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| MaaT Pharma · EURONEXT:MAAT | US$16.11M | US$23.36M | n/a | 4.7× | n/a | n/a | −686.6% | n/a | n/a |
| SynCore Biotechnology Co., Ltd. · TPEX:4192 | US$16.80M | US$12.38M | n/a | 15.6× | n/a | 2.5× | −178.5% | 0.0× | n/a |
| Initiator Pharma A/S · OMXSTO:INIT | US$16.74M | US$15.65M | n/a | n/a | n/a | 13.4× | n/a | 1.1× | n/a |
| Neurotech International Ltd. · ASX:NTI | US$16.63M | US$15.06M | n/a | n/a | n/a | 41.1× | n/a | 0.0× | n/a |
| Akari Therapeutics PLC · NASDAQ:AKTX | US$16.41M | US$10.66M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.49 |
| Lipocine Inc. · NASDAQ:LPCN | US$16.39M | −US$5.07M | n/a | −1.4× | n/a | 0.8× | −249.2% | 0.0× | 1.18 |
| Elicera Therapeutics AB · OMXSTO:ELIC | US$16.09M | US$10.40M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| Pasithea Therapeutics Corp. · NASDAQ:KTTA | US$16.00M | −US$25.22M | n/a | n/a | −0.1× | 0.4× | n/a | 0.0× | 0.97 |
| Atossa Therapeutics, Inc. · NASDAQ:ATOS | US$15.92M | −US$4.66M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.87 |
| Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX | US$15.76M | −US$17.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.68 |
| Celularity Inc. · NASDAQ:CELU | US$15.02M | US$50.46M | n/a | 2.7× | n/a | n/a | −117.3% | n/a | 1.47 |
| Median of the others | US$16.24M | US$10.53M | 2.7× | −0.1× | 0.9× | −178.5% | 0.0× | 1.08 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 3.00 EUR · Analysts' mean
- EPS, year to Dec 2026
- -2.12 · 3 analysts
- Revenue, year to Dec 2026
- 5.78M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Hervé Affagard | CEO and co-founder |
| Eric Soyer | Chief Financial Officer |
| Guilhaume DEBROAS | MaaT Pharma – Investor Relations |
Board
| Director | Role |
|---|---|
| Jean-Marie Lefevre | Chairman of the Board – Non-Executive Director |
| Claude Bertrand | Independent director |
| Hervé Affagard | CEO and co-founder |
| Isabelle de Crémoux | Non-Executive Director |
| Jean Volatier | Independent director |
| Muriel Prudent | Non-Executive Director |
| Nadia Kamal | Independent director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Mar 30, 2026 | −16.0% |
| Quarter to Sep 30, 2025 | Nov 4, 2025 | −1.4% |
| Q2 2025 | Sep 17, 2025 | −4.7% |
| Quarter to Mar 31, 2025 | Apr 14, 2025 | +5.1% |
| Q4 2024 | Mar 27, 2025 | 0.0% |
| Quarter to Sep 30, 2024 | Nov 5, 2024 | +1.9% |
| Q2 2024 | Sep 19, 2024 | +2.8% |
| Q1 2024 | Apr 2, 2024 · After close | +0.5% |
| Q4 2023 | Mar 28, 2024 | −5.0% |
| Q3 2023 | Nov 9, 2023 · After close | −2.4% |
All 17 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Jul 27, 2023 · After close | −3.1% |
| Q1 2023 | May 9, 2023 · After close | −3.7% |
| Q4 2022 | Mar 30, 2023 | +3.1% |
| Q3 2022 | Nov 8, 2022 · After close | −1.1% |
| Q2 2022 | Jul 28, 2022 · After close | +1.0% |
| Q1 2022 | Apr 14, 2022 · Before open | 0.0% |
| Q3 2021 | Oct 20, 2021 · Before open |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 27 slides | October 2026 |
| Investor Presentation (September 2026) | Investor deck | 28 slides | September 2026 |
| Investor Presentation (July 2026) | Investor deck | 28 slides | July 2026 |
| Shareholder Meeting (June 2026) | Shareholder meeting | 32 slides | Jun 16, 2026 |
| Investor Presentation (March 2026) | Investor deck | 28 slides | March 2026 |
| Investor Presentation (October 2025) | Investor deck | 31 slides | October 2025 |
| Investor Presentation (April 2025) | Investor deck | 32 slides | April 2025 |
| Investor Presentation (February 2025) | Investor deck | 32 slides | February 2025 |
| Investor Presentation (January 2025) | Investor deck | 33 slides | January 2025 |
| Technical Presentation (December 2024) | Technical | 25 slides | December 2024 |
All 27 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2024) | Investor deck | 22 slides | November 2024 |
| Investor Presentation (October 2024) | Investor deck | 34 slides | October 2024 |
| EBMT 2024 | Conference | 20 slides | October 2024 |
| Investor Presentation (May 2024) | Investor deck | 30 slides | May 2024 |
| Investor Presentation (April 2024) | Investor deck | 30 slides | April 2024 |
| Investor Presentation (March 2024) | Investor deck | 31 slides | March 2024 |
| Investor Presentation (January 2024) | Investor deck | 31 slides | January 2024 |
| Investor Presentation (December 2023) | Investor deck | 30 slides | December 2023 |
| Investor Presentation (September 2023) | Investor deck | 37 slides | September 2023 |
| Investor Presentation (July 2023) | Investor deck | 37 slides | July 2023 |
| Investor Presentation (June 2023) | Investor deck | 37 slides | June 2023 |
| Investor Presentation (January 2023) | Investor deck | 37 slides | January 2023 |
| Investor Presentation (August 2022) | Investor deck | 32 slides | August 2022 |
| Investor Day (June 2022) | Investor day | 93 slides | Jun 7, 2022 |
| Investor Presentation (May 2022) | Investor deck | 29 slides | May 6, 2022 |
| Investor Presentation (March 2022) | Investor deck | 29 slides | Mar 29, 2022 |
| Investor Presentation (January 2022) | Investor deck | 29 slides | Jan 23, 2022 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new ordinary shares Closed: €9.1M raised · €3.48 a share · Portzamparc, BNP Paribas Group Dealers: Portzamparc, BNP Paribas Group (lead) Buyers: PSIM represented by Bpifrance Investissement (pledged to subscribe for €1.5 million); Biocodex (€1.5 million); Fonds PSIM (Bpifrance Investissement) (€1.5 million); Invus Public Entities (€1.5 million) Insiders: Existing shareholders PSIM (Bpifrance Investissement) and Biocodex pledged to subscribe €1.5 million each, €3 million in total; Biocodex's president is a board member Use of proceeds: Fund its roadmap: preparing Xervyteg commercialization, MaaT033 development, FDA discussions, working capital and general corporate purposes | Nov 14, 2025 | US$10.58M |
| Loan with warrants attached Tranche closed: €3.5M raised · Warrants at €4.5898 for 240 months · Van Lanschot Kempen Dealers: Van Lanschot Kempen Buyers: European Investment Bank (EIB) (€37.5 million, 4-tranche loan with warrants attached); European Investment Bank (Tranche A loan of €3.5 million and 468,772 warrants) Use of proceeds: Advance late-stage hemato-oncology programs, including Xervyteg and MaaT033 | Nov 4, 2025 | US$4.02M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.52M | 3.22M | 2.23M | 1.43M | 972.0K | 0 | 89.3K | 892.0K | 109.3K |
| Cost of revenue | 3.13M | 1.25M | 1.44M | 339.0K | 166.0K | 164.0K | 97.0K | 79.0K | 3.50M |
| Gross profit | 1.39M | 1.97M | 784.0K | 1.09M | 806.0K | -164.0K | -7.70K | 813.0K | -3.39M |
| Research and development | 27.6M | 27.5M | 20.3M | 14.5M | 9.14M | 6.10M | 5.27M | 4.51M | |
| Selling, general and administrative | 8.22M | 2.66M | 2.35M | 1.47M | 1.17M | 1.29M | 922.0K | 787.0K | |
| Operating income | -34.1M | -28.4M | -19.9M | -13.6M | -8.89M | -7.39M | -4.96M | -4.40M | -4.71M |
| Depreciation and amortization | 1.74M | 1.69M | 871.0K | 429.0K | 328.0K | 164.0K | 97.0K | 79.0K | 51.2K |
| EBITDA | -32.4M | -26.7M | -19.1M | -13.1M | -8.56M | -7.22M | -4.87M | -4.33M | -4.66M |
| Interest expense | 1.27M | 868.0K | 413.0K | 201.0K | 121.0K | 45.0K | 20.0K | 71.0K | 0 |
| Income before tax | -34.9M | -32.4M | -19.7M | -13.7M | -9.02M | -6.79M | -5.84M | -4.47M | -4.78M |
| Income tax | -3.79M | -3.52M | -3.63M | 157.0K | 121.0K | -1.49M | 803.0K | 71.0K | -922.8K |
| Net income | -31.1M | -28.9M | -19.7M | -13.7M | -9.02M | -5.35M | -6.65M | -4.55M | -3.86M |
| Earnings per share, basic | -1.95 | -2.21 | -1.73 | -1.39 | -3.72 | -25.91 | -32.20 | -4.40 | -3.74 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 24.9M | 20.2M | 24.3M | 35.2M | 43.3M | 19.9M | 5.41M | 3.60M | 7.35M |
| Short-term investments | 95.0K | 66.0K | 34.0K | 63.0K | |||||
| Receivables | 6.82M | 1.51M | 5.16M | 1.05M | 3.51M | 2.24M | 1.50M | 794.0K | 4.23K |
| Inventory | 84.0K | 64.0K | 190.0K | 47.0K | 33.0K | -97.0K | 27.4K | 1 | 28.9K |
| Current assets | 33.0M | 27.6M | 32.0M | 42.1M | 47.3M | 22.2M | 6.98M | 4.73M | 8.79M |
| Property, plant and equipment | 7.33M | 8.60M | 9.17M | 966.0K | 1.11M | 1.10M | 428.0K | 391.0K | 313.0K |
| Goodwill | 44.1K | ||||||||
| Total assets | 44.6M | 38.5M | 42.9M | 44.7M | 49.4M | 24.3M | 8.17M | 5.88M | 9.26M |
| Accounts payable | 11.8M | 8.83M | 6.35M | 4.51M | 34.0K | 1.40M | 1.68M | 1.42M | 1.14M |
| Current liabilities | 17.0M | 14.6M | 11.5M | 9.22M | 4.70M | 2.86M | 2.63M | 2.24M | 1.45M |
| Long-term debt | 11.0M | 7.80M | 5.42M | 7.93M | 3.96M | 4.72M | 9.92M | 2.17M | |
| Total debt | 17.4M | 16.0M | 14.1M | 11.4M | 5.81M | 6.08M | 10.5M | 2.60M | 1.72M |
| Total liabilities | 42.8M | 28.2M | 22.5M | 17.9M | 9.56M | 8.34M | 12.7M | 4.62M | 3.99M |
| Shareholders' equity | 1.80M | 10.3M | 20.5M | 26.8M | 39.9M | 15.9M | -4.57M | 1.27M | 5.27M |
| Shares outstanding | 15.9M | 13.1M | 11.4M | 9.89M | 2.43M | 206.5K | 206.5K | 1.03M | 1.03M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -15.9M | -22.0M | -18.7M | -12.6M | -7.93M | -5.81M | -5.02M | -3.87M | -3.87M |
| Capital spending | -609.0K | -753.0K | -1.09M | -662.0K | -238.0K | -316.0K | -128.0K | -291.0K | -291.0K |
| Free cash flow | -16.5M | -22.8M | -19.8M | -13.3M | -8.17M | -6.13M | -5.15M | -4.16M | -4.16M |
| Cash from investing | -497.0K | -416.0K | -440.0K | -815.0K | -238.0K | -523.0K | -154.0K | -311.0K | -311.0K |
| Cash from financing | 21.1M | 18.3M | 8.14M | 5.36M | 31.6M | 20.8M | 6.98M | 432.0K | 432.0K |
| Share buybacks | -45.0K | 17.3M | -79.0K | -137.0K | 32.4M | 18.0M | 0 | 28.0K | |
| Change in cash | 4.71M | -4.13M | -11.0M | -8.06M | 23.4M | 14.5M | 1.81M | -3.75M | -3.75M |
Cap table
Built by 6ix from MaaT Pharma’s releases · as of Nov 14, 2025
- Common shares
- 18,824,425
- Fully diluted
- 18,824,425
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 18,824,425 |
Warrants and options
| Lot |
|---|
| Warrants · €4.59 · expire about Nov 2045 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 18,824,425 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Claude Bertrand | Independent director · Since at least Jun 24, 2025 |
| Eric Soyer | Chief Financial Officer · Since at least Oct 19, 2026 |
| Guilhaume DEBROAS | MaaT Pharma – Investor Relations · Since at least Dec 8, 2025 |
| Hervé Affagard | CEO and co-founder · Since at least Oct 19, 2026 |
| Isabelle de Crémoux | Non-Executive Director · Since at least Nov 5, 2026 |
| Jean-Marie Lefevre | Chairman of the Board – Non-Executive Director · Since at least Jun 24, 2025 |
| Jean Volatier | Independent director · Since at least Jun 24, 2025 |
| Muriel Prudent | Non-Executive Director · Since at least Nov 5, 2026 |
| Nadia Kamal | Independent director · Since at least Jun 24, 2025 |
Log in to ask 6ix AI your own questions about MaaT Pharma.